NCT04402476

Brief Summary

Skin Sensitization Test (Modified Draize-95) to Support a Low Dermatitis Potential Claim for a Powder Free Polychloroprene Surgical Gloves, Sterile. To evaluate whether residual chemical additives at a level on the gloves that may induce type IV allergy to the unsensitized general user population when using polychloroprene based surgical gloves

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 23, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 6, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 20, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 26, 2020

Completed
Last Updated

June 17, 2020

Status Verified

June 1, 2020

Enrollment Period

3 months

First QC Date

May 20, 2020

Last Update Submit

June 15, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Induction Phase

    Irritation scored by Erythemal Scoring Scale, Basic Score - Description: 0 - No visible reaction. 0.5 - Doubtful or Negligible Erythema Reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled / follicular, patchy or confluent pattern (slight pinking). 2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site.

    24 days

  • Challenge Phase

    Irritation scored by Erythemal Scoring Scale, Basic Score - Description : 0 - No visible reaction. 0.5 - Doubtful or Negligible Erythema Reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled / follicular, patchy or confluent pattern (slight pinking). 2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site.

    48 hours

Study Arms (1)

Device and Control

EXPERIMENTAL

Device: Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs. Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact. Positive Control: 0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml

Device: Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.

Interventions

Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.

Device and Control

Eligibility Criteria

Age18 Years - 65 Years
Sexall(Gender-based eligibility)
Gender Eligibility Details104 female (50%) and 104 male (50%)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The test subjects are normal volunteers who have documented informed consent and have not participated in other voluntary testing for at least 30 days.
  • Age of the test subjects ranged from 18 to 65 years.
  • Efforts are made to provide racial and gender diversity of the test subjects that reasonably reflects the general user population in the US

You may not qualify if:

  • The test subjects with any visible skin disease that might be confused with skin reactions caused by the test material.
  • The test subjects with any indication of existing Type I allergy to natural rubber proteins.
  • The test subjects who have used corticosteroids, either systemically or topically on the potential test site, two weeks before testing.
  • Test subjects who have received endogenous or exogenous immunosuppressive treatments (or prolonged sun exposure).
  • All subjects who are pregnant or become pregnant during the study.
  • All lactating women,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Makmal Bioserasi & Klinikal, Healthmedic Research Sdn. Bhd.

Kuala Lumpur, Cheras, 56000, Malaysia

Location

Related Publications (3)

  • Foy V, Weinkauf R, Whittle E, Basketter DA. Ethnic variation in the skin irritation response. Contact Dermatitis. 2001 Dec;45(6):346-9. doi: 10.1034/j.1600-0536.2001.450605.x.

  • Kompaore F, Tsuruta H. In vivo differences between Asian, black and white in the stratum corneum barrier function. Int Arch Occup Environ Health. 1993;65(1 Suppl):S223-5. doi: 10.1007/BF00381346.

  • Robinson MK. Population differences in acute skin irritation responses. Race, sex, age, sensitive skin and repeat subject comparisons. Contact Dermatitis. 2002 Feb;46(2):86-93. doi: 10.1034/j.1600-0536.2002.460205.x.

Related Links

Study Officials

  • Dr. Saadiah Sulaiman, Dermatologist, MBBCh, MMED

    Makmal Bioserasi & Klinikal, Healthmedic Research Sdn. Bhd.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Powder Free Polychloroprene Surgical Glove, Sterile. Low Dermatitis Potential, tested for use with chemotherapy drugs
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2020

First Posted

May 26, 2020

Study Start

November 23, 2019

Primary Completion

February 20, 2020

Study Completion

April 6, 2020

Last Updated

June 17, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations